Neuroprotective compositions and their use
US-2018360801-A1 · Dec 20, 2018 · US
Compositions for the management of seizure induced neurotoxicity
US12465585B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12465585-B2 |
| Application number | US-202117365519-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 1, 2021 |
| Priority date | Jun 15, 2018 |
| Publication date | Nov 11, 2025 |
| Grant date | Nov 11, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use reducing the incidence of seizures and in the management of neurotoxicity induced by seizures.
First claim
Opening claim text (preview).
We claim: 1 . A method for preventing apoptosis in neuronal cells of mammals with epilepsy, said method comprising step of: a) identifying a mammal with signs and features of neurotoxicity induced by seizures and b) administering effective concentration of a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin, to said mammals to prevent apoptosis of neurons. 2 . The method as in claim 1 , wherein the composition comprises 10%-15% w/w of oroxylin A, 10%-25% w/w of baicalein and 2%-10% w/w of chrysin. 3 . The method as in claim 1 , wherein prevention of apoptosis is brought about by decreasing caspase-1 and caspase-3 activity. 4 . The method as in claim 1 , wherein the mammal is human.
Assignees
Inventors
Classifications
condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} · CPC title
Antiepileptics; Anticonvulsants · CPC title
- A61K9/0053Primary
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
- A61K31/353Primary
3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12465585B2 cover?
- The present invention discloses a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use reducing the incidence of seizures and in the management of neurotoxicity induced by seizures.
- Who is the assignee on this patent?
- Majeed Muhammed, Nagabhushanam Kalyanam, Sami Sabinsa Group Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K9/0053. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).